LQDA Liquidia Corporation
USHealthcareAs of 2026-08-24
Why LQDA matters now
Liquidia Corporation (LQDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $70.27 with +2.40% on the session and $6.25B in market capitalization; recent performance reads 1-month +18.49% and YTD +106.06%.
The latest financial table shown here is Q1 2026, with revenue of $132.9M, net income of $52.9M, and EPS of $0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.7%.
The latest indexable market news headline is "Will LQDA's Differentiated PAH Approach Drive Growth?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $68.00; recent insider activity includes Manning Paul B filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
57.60
P/S
21.94
EV/EBITDA
116.78
DCF Value
$-83.75
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.8%
Operating Margin
15.8%
Net Margin
7.7%
ROE
46.8%
ROA
5.6%
ROIC
12.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $132.9M | $52.9M | $0.52 |
| Q4 2025 | $92.0M | $14.6M | $0.15 |
| FY 2025 | $158.3M | $-68.9M | $-0.80 |
| Q3 2025 | $54.3M | $-3.5M | $-0.04 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$68.00
Target (Median)
$68.00
Target Range
$60.00 - $75.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.59
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.